Skip to product information
1 of 1

MULTI SCIENCES

Human ErBB2/HER2/CD340 ELISA Kit Plate

Human ErBB2/HER2/CD340 ELISA Kit Plate

SKU:EK1182

Regular price Send Inquiry
Regular price Sale price Send Inquiry
Sale Sold out
View full details

Product Details

Human ErBB2/HER2/CD340 ELISA Kit Plate

Brand

MultiSciences

Cat Num

70-EK1182

Product Name

Human ErbB2/HER2/CD340 ELISA Kit

Customs Name

Human ErbB2/HER2/CD340 ELISA Kit

Application

ELISA

Reactivity

Human

Assay Type

Sandwich ELISA

Suitable Sample Type

serum, plasma, cell culture supernates

Format

96-well strip plate

Storage

4℃ (unopened)standard stored at -20℃, others stored at 4℃ (opened)

Shipping Condition

4℃

Sample Volume

100 μl (prediluted)

Sensitivity

0.51 pg/ml

Standard Curve Range

31.25 - 2000 pg/ml

Spike Recovery Range

85 % - 112 %

Mean Spike Recovery

1.06

CV of Intra plate

1.9 % - 3.2 %

CV of Inter plate

2.1 % - 3.7 %

Components

96-well polystyrene microplate coated with a monoclonal antibody against ErbB2
Human ErbB2 Standard, lyophilized
ErbB2 Detect Antibody
Assay Buffer (10×)
Substrate (TMB)
Stop Solution
Washing Buffer (20×)
Plate Covers

Describtion

This assay employs the quantitative sandwich enzyme immunoassay technique for the quantitative detection of human ErbB2. The Human ErbB2/HER2/CD340 ELISA is for research use only. Not for diagnostic or therapeutic procedures.
ErbB2, is a protein that in humans is encoded by the ERBB2 gene, which is also frequently called HER2 (from human epidermal growth factor receptor 2) or CD340. HER2 contain an extracellular ligand binding domain, a transmembrane domain, and an intracellular domain that can interact with a multitude of signaling molecules and exhibit both ligand-dependent and ligand-independent activity. Amplification or overexpression of this oncogene has been shown to play an important role in the development and progression of certain aggressive types of breast cancer. In recent years the protein has become an important biomarker and target of therapy for approximately 30% of breast cancer patients.